UK’s Biotecnol strikes a deal with CRUK to move new immuno-oncology drug into PhI
London-based Biotecnol has struck a deal with Cancer Research UK to move its lead immune-oncology drug into an open-label Phase I test. The pact lends …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
